Treat Action Group 2023 Pipeline Report

resisttb
Apr 25, 2024
1 min read

Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full report here.

Recent Posts

See All

Life-saving DR-TB treatments even more affordable following newest bedaquiline price decrease

The lowest cost of the full BPaLM regimen, which is the most recommended treatment for drug resistant tuberculosis (DR-TB), has now...

New study affirms financial and public health advantages of treating drug-resistant TB with BPaL-Based Regimens in India

Researchers at the ICMR National Institute for Research in Tuberculosis conducted an economic evaluation study, focused on India, that...

11,000 more TB patients died after Trump's USAID cuts. That number will rise.

President Donald Trump has cut around $2.5 billion in funding to USAID health programs since his inauguration, limiting funding and...

Comments